NiKang Therapeutics: Latest News, Top Stories & Analysis

WILMINGTON, DE — NiKang Therapeutics Inc. announced it has completed dosing in the first patient cohort of its Phase 1 dose-escalation study evaluating NKT5097, an oral small molecule designed to …

Regional

NiKang Advances CDK2 Degrader with Key Milestone in Cancer Treatment Trial

March 16, 2025March 15, 2025 - by Timothy Alexander

WILMINGTON, DE — NiKang Therapeutics® Inc. has achieved a pivotal step in the development of its first-in-class CDK2 degrader, NKT3964, by completing the dosing of the first patient cohort in a …